By Ben Glickman


Cigna Group-owned Evernorth Health Services said Thursday it would provide a Humira biosimilar with no out-of-pocket fees starting in June.

The pharmacy and benefits provider said the biosimilar for Humira, used as a treatment for rheumatoid arthritis, Crohn's disease and other inflammatory conditions, would be available to eligible patients at its specialty pharmacy Accredo.

The company said the biosimilar price would be about 85% lower than the Humira list price. Evernorth said more than 100,000 Accredo patients currently use Humira or a biosimilar.

Plans for a $0 out-of-pocket Humira biosimilar offering was initially announced by Evernorth in March.


Write to Ben Glickman at ben.glickman@wsj.com


(END) Dow Jones Newswires

04-25-24 1725ET